Search in:

Advanced search

International Journal of Chronic Obstructive Pulmonary Disease Volume 12, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

Edward M Kerwin1 Clinical Research Institute of Southern Oregon, Medford, ORCorrespondence[email protected]

Chris J Kalberg2 Respiratory Department, GlaxoSmithKline, Research Triangle Park, NC, USA

Dmitry V Galkin2 Respiratory Department, GlaxoSmithKline, Research Triangle Park, NC, USA

Chang-Qing Zhu3 Clinical Statistics, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex

Alison Church2 Respiratory Department, GlaxoSmithKline, Research Triangle Park, NC, USA

John H Riley4 Respiratory Department, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, UK

William A Fahy4 Respiratory Department, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, UK

show all

Pages 745-755 | Published online: 24 Feb 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

DransfieldMTBaileyWCraterGEmmettAO’DellDMYawnBDisease severity and symptoms among patients receiving monotherapy for COPDPrim Care Respir J2011201465320886200
PubMedGoogle Scholar
GOLD [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease2016 [cited July 25, 2016]. Available from: http://www.goldcopd.com/Accessed January 4, 2017
Google Scholar
BlairHADeeksEDUmeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary diseaseDrugs2015751617425398674
PubMed Web of Science ®Google Scholar
GSKANORO™ ELLIPTA® [prescribing information]2014 Available from: https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDFAccessed September 2015
Google Scholar
GSK [webpage on the Internet]ANORO™ ELLIPTA® summary of product characteristics2014 Available from: http://www.medicines.org.uk/emc/medicine/28949#INDICATIONSAccessed September 2015
Google Scholar
DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
PubMed Web of Science ®Google Scholar
Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
PubMed Web of Science ®Google Scholar
DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
PubMed Web of Science ®Google Scholar
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice E6(1)1996 [cited May 2013]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdfAccessed January 4, 2017
Google Scholar
World Medical Association [webpage on the Internet]WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects2013 [cited May 2013]. Available from: http://www.wma.net/en/30publications/10policies/b3/index.htmlAccessed January 4, 2017
Google Scholar
CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
PubMed Web of Science ®Google Scholar
Boehringer Ingelheim [webpage on the Internet]SPIRIVA® HANDIHALER® summary of product characteristics2004 Available from: https://www.medicines.org.uk/emc/medicine/10039Accessed April 16, 2016
Google Scholar
Boehringer Ingelheim, SPIRIVA® HANDIHALER® [prescribing information]2004 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdfAccessed April 16, 2016
Google Scholar
MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
PubMedGoogle Scholar
JonesPWSt. George’s respiratory questionnaire: MCIDCOPD200521757917136966
PubMedGoogle Scholar
KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
PubMed Web of Science ®Google Scholar
CalzettaLRoglianiPMateraMGSystematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
PubMed Web of Science ®Google Scholar
BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
PubMed Web of Science ®Google Scholar
SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
PubMed Web of Science ®Google Scholar
CalverleyPMRennardSIWhat have we learned from large drug treatment trials in COPD?Lancet2007370958977478517765527
PubMed Web of Science ®Google Scholar
CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
PubMed Web of Science ®Google Scholar
CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
PubMed Web of Science ®Google Scholar
CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
PubMed Web of Science ®Google Scholar
TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
PubMed Web of Science ®Google Scholar
ObaYSarvaSTDiasSEfficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date